In This Section
Craig M. Crews, PhD

Craig M. Crews, PhD

Yale School of Medicine
New Haven, Connecticut

Class of 2024

For trailblazing research involving the use of small molecules to manipulate intracellular protein levels via targeted protein degradation, pioneering the development of proteolysis-targeting chimeras (PROTACs), and leading critical investigations concerning synthetic proteasome inhibitors such as carfilzomib, approved for the treatment of multiple myeloma.

*Full-length biography pending